1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan
Key Takeaways
The annual well-woman visit integrates age-tailored health history, individualized physical examination, immunizations, and preventive screening across four core developmental phases: adolescence, reproductive age, perimenopause, and postmenopause.
Sexual history taking should be structured around the CDC 5 Ps: Partners, Practices, Protection from STIs, Past history of STIs, and Pregnancy intention, using open-ended, nonjudgmental language.
Guidance on screening pelvic exams differs: ACOG (Committee Opinion 754) advises pelvic exams when history or symptoms indicate them and shared decision-making for asymptomatic patients, while the USPSTF finds the evidence insufficient (I statement).
Adult immunization priorities for women include HPV vaccination through age 26 (and shared clinical decision-making ages 27–45), Tdap during each pregnancy between 27 and 36 weeks gestation, universal hepatitis B vaccination for adults aged 19–59, and seasonal maternal RSV immunization at 32–36 weeks.
Routine primary care preventive screening includes universal colorectal cancer screening starting at age 45, diabetes screening starting at age 35 for individuals with overweight or obesity, and DEXA bone density screening at age 65, or earlier when a formal risk tool such as FRAX or OST shows increased fracture risk in a postmenopausal woman (USPSTF 2025).
Lifespan Care & The Annual Well-Woman Visit
The annual well-woman visit provides a dedicated platform to deliver preventive screening, counsel on reproductive choices, administer immunizations, and optimize chronic conditions. Priorities evolve across four core lifespan epochs:
- Adolescence (Ages 13–21): The initial visit should occur between ages 13 and 15 to build rapport, assess pubertal development, and evaluate psychosocial health using HEEADSSS (Home, Education, Eating, Activities, Drugs, Sexuality, Suicide, Safety). Clinicians must clarify confidentiality boundaries. Routine speculum and bimanual exams are not indicated in asymptomatic adolescents, even when initiating contraception.
- Reproductive Age (Ages 21–39): Care centers on reproductive life planning, contraception, preconception counseling (daily folic acid: 0.4 mg average risk, 4.0 mg high risk), intimate partner violence (IPV) screening, and cervical cancer screening beginning at age 21.
- Perimenopause & Menopausal Transition (Ages 40–64): Focus shifts to managing ovulatory shifts, vasomotor symptoms, abnormal bleeding, and metabolic risks. Colorectal cancer screening initiates at age 45 alongside biennial screening mammography and cardiovascular risk profiling.
- Postmenopause & Older Adults (Ages 65+): Priorities center on functional mobility, fall prevention, cognitive screening, genitourinary syndrome of menopause (GSM), polypharmacy review, and universal osteoporosis screening with central DEXA at age 65.
Health History & The 5 Ps of Sexual Health
Obtaining an accurate, trauma-informed sexual and reproductive history requires open-ended communication. The CDC structures this assessment around the 5 Ps:
| Domain | Core Clinical Inquiries | Key Objectives |
|---|---|---|
| 1. Partners | "Do you have sex with men, women, or both? In the past 12 months, how many partners have you had?" | Identifies transmission networks and directs anatomical testing sites (cervical, pharyngeal, rectal). |
| 2. Practices | "What sexual contact do you have: vaginal, anal, or oral? Do you use sex toys or barrier devices?" | Directs extragenital NAAT screening and evaluates tissue trauma risk. |
| 3. Pregnancy Intention | "What are your plans regarding pregnancy? What methods do you use to prevent pregnancy?" | Assesses pregnancy intention, contraceptive efficacy, and preconception optimization needs. |
| 4. Protection from STIs | "How do you protect against STIs and HIV? How consistently do you use condoms?" | Evaluates barrier consistency and determines eligibility for HIV pre-exposure prophylaxis (PrEP). |
| 5. Past History of STIs | "Have you or any partners ever been diagnosed with or treated for an STI?" | Flags risk for recurrent infections, pelvic inflammatory disease (PID), and tubal scarring. |
Note
Clinicians increasingly evaluate a sixth "P"—Pleasure—assessing dyspareunia, sexual satisfaction, and pelvic floor function during the well-woman visit.
Physical Examination Guidelines & Pelvic Exam Debate
A comprehensive exam includes vital signs, BMI, thyroid assessment, cardiopulmonary auscultation, abdominal palpation, and age-appropriate breast and pelvic examinations.
Asymptomatic Screening Pelvic Exam Controversy
- ACOG (Committee Opinion 754, 2018): Recommends pelvic examinations when indicated by medical history or symptoms. For asymptomatic, nonpregnant patients, whether to perform an external or internal exam is a shared decision. ACOG acknowledges the exam does not screen for ovarian cancer, while noting possible benefits such as vulvar inspection and patient reassurance.
- USPSTF: Issues an I statement (insufficient evidence) regarding routine screening pelvic exams in asymptomatic, nonpregnant women. Bimanual palpation exhibits sensitivity under 30% and very low positive predictive value for early ovarian cancer, triggering unnecessary testing and surgery.
Indications for Diagnostic Pelvic Examination
A complete speculum and bimanual exam is mandatory for clinical signs: unexplained pelvic pain, abnormal bleeding, dyspareunia, abnormal discharge, suspected prolapse/mass, cervical cytology collection, and IUD insertion or string checks.
Adult & Maternal Immunization Protocols
Immunization records must be audited at every preventive encounter:
- Human Papillomavirus (HPV; 9-valent): Routine at age 11–12 (can start at 9); catch-up through age 26; shared decision-making for ages 27–45. FDA-labeled dosing is 2 doses (0, 6–12 months) if started before age 15 and 3 doses (0, 1–2, 6 months) if started at 15 or older or if immunocompromised; an interrupted series is never restarted. In January 2026 CDC's revised childhood schedule moved to a single HPV dose (a change not voted by ACIP), so confirm the current federal and professional-society schedule before counseling.
- Tdap: Routine booster every 10 years. Administer one dose during each pregnancy between 27 and 36 weeks gestation to maximize transplacental IgG pertussis antibodies to the fetus.
- Influenza: Annually for all persons ≥6 months. Inactivated (IIV) or recombinant (RIV) vaccines are safe during any trimester. Live attenuated vaccine (LAIV) is contraindicated in pregnancy.
- MMR & Varicella: Live attenuated vaccines are contraindicated in pregnancy. Avoid pregnancy for 28 days (4 weeks) post-vaccination. Administer postpartum if non-immune.
- Hepatitis B: Universal vaccination for all adults aged 19–59, and adults ≥60 with risk factors. Universal HBsAg screening is standard in every pregnancy.
- Pneumococcal: Since October 2024, ACIP recommends a pneumococcal conjugate vaccine for all adults aged 50 and older (and adults 19–49 with risk conditions): PCV20 or PCV21 alone, or PCV15 followed by PPSV23 one year later.
- Herpes Zoster (Shingrix): Recombinant vaccine (2 doses at 0, 2–6 months) for adults aged 50+ and immunocompromised adults aged 19+.
- RSV (Abrysvo): Maternal bivalent vaccine given at 32 to 36 weeks gestation from September through January to protect infants from severe lower respiratory tract disease. A single adult RSV dose is recommended for everyone aged 75 and older and for adults 50–74 at increased risk (chronic heart, lung, kidney, or metabolic disease, immunocompromise, or nursing-home residence).
Note
Federal vaccine recommendations changed repeatedly during 2025–2026 (for example, CDC moved COVID-19 vaccination to individual-based decision-making). ACOG published its own 2026 Maternal Immunization Schedule, endorsed by NPWH and 12 other organizations. It continues to recommend Tdap, inactivated influenza, COVID-19, and seasonal RSV (Abrysvo) vaccination in pregnancy.
Routine Preventive Screening Schedule
| Screening Domain | Target Population | Modality | Frequency & Clinical Guidance |
|---|---|---|---|
| Lipids | Adults aged 20+ (2026 ACC/AHA guideline) | Fasting or non-fasting lipid profile; lipoprotein(a) at least once | Repeat every 4–6 years at average risk; estimate 10-year risk with PREVENT-ASCVD at ages 30–79. |
| Diabetes / Prediabetes | Asymptomatic adults aged 35–70 with BMI ≥25 (≥23 in Asian Americans) | Fasting glucose, HbA1c, or 2-hr OGTT | Every 3 years. Screen earlier if high-risk (PCOS, gestational diabetes history). |
| Colorectal Cancer | Average-risk adults aged 45 to 75 | Colonoscopy, annual FIT, or sDNA-FIT | Colonoscopy every 10 years, annual FIT, or sDNA-FIT every 1–3 years. |
| Osteoporosis (DEXA) | All women aged 65+; postmenopausal women <65 with elevated risk | Central DEXA (femoral neck and spine) | Universal at age 65 (USPSTF 2025, grade B). If postmenopausal and under 65, screen when a formal clinical risk tool (FRAX, OST, or ORAI) shows increased risk; the 2025 statement sets no single FRAX cutoff. |
| Lung Cancer | Adults aged 50–80 with ≥20 pack-years who smoke now or quit within 15 years | Annual low-dose CT | Stop after 15 smoke-free years or when health limits benefit (USPSTF 2021). |
Tip
In postmenopausal women under age 65, first look for risk factors (low body weight, parental hip fracture, smoking, excess alcohol, glucocorticoid use), then apply a validated tool such as FRAX or OST. Older USPSTF statements compared a woman's FRAX risk with that of an average 65-year-old White woman (9.3% in 2011, 8.4% in 2018); the 2025 statement names no threshold.
A 27-year-old woman planning to conceive in about 6 months has a negative rubella IgG and a negative varicella IgG with no record of varicella vaccination. Her urine pregnancy test today is negative, and she uses condoms consistently. What is the most appropriate immunization plan?
Defer both vaccines until she is pregnant so that maternal antibodies form when the fetus needs them.
Give MMR now, but never give varicella vaccine to a woman who may become pregnant in the future.
Give MMR and varicella dose 1 now and dose 2 in 4–8 weeks; avoid pregnancy for 1 month after each dose.
Give varicella-zoster immune globulin now in place of the varicella vaccine series, and repeat it yearly.
A 52-year-old postmenopausal female presents for a routine health maintenance visit. She has a 25 pack-year smoking history, a body mass index (BMI) of 20.8 kg/m², and takes no daily medications. She has never had an osteoporotic fracture. Her mother sustained a hip fracture at age 72. The patient asks whether she needs bone density testing and colon cancer screening. What is the most appropriate management plan?
Reassure the patient that DEXA scanning begins at age 65 for all women and defer colorectal cancer screening until age 55.
Initiate colorectal cancer screening today and calculate a FRAX score to determine if a DEXA scan is indicated before age 65.
Order a screening colonoscopy immediately, but withhold bone mineral density testing until she reaches surgical or natural menopause for 10 years.
Order both a DEXA scan and screening colonoscopy today based solely on her chronological age.
An asymptomatic 28-year-old nulligravida presents for a routine checkup. She has no chronic medical conditions, no pelvic symptoms, and normal menstrual cycles. Her mother was diagnosed with ovarian cancer at age 68. The patient requests an annual bimanual pelvic examination to ensure her ovaries are normal. Which statement represents the best evidence-based guidance regarding screening pelvic examinations in this patient?
ACOG and USPSTF both issue Grade A recommendations for annual bimanual screening pelvic exams to detect occult ovarian carcinoma in reproductive-age women.
Annual bimanual pelvic examination has a 90% sensitivity for detecting asymptomatic early-stage adnexal malignancies and should be performed routinely.
USPSTF finds the evidence insufficient for routine screening pelvic exams in asymptomatic nonpregnant women; bimanual exams do not screen for ovarian cancer.
Screening bimanual examinations are contraindicated in women under age 35 due to high rates of iatrogenic adnexal torsion.
Sections you finish are checked off in the contents.